Viewing Study NCT02122861

Home

Certify Doc

Genes

Clinical Trials

CompTox

DrugMatrix

Open Targets

Products

Support

Bugs

Main Search All Studies All Organizations Report Bug

Ignite Creation Date: 2025-12-24 @ 12:34 PM

Ignite Modification Date: 2025-12-24 @ 12:34 PM

Study NCT ID: NCT02122861

Status: COMPLETED

Last Update Posted: 2019-03-06

First Post: 2014-04-22

Is Possible Gene Therapy: False

Has Adverse Events: False

Brief Title: Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1

Sponsor: Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module